Portfolio of Immune Checkpoint Inhibitor Stocks

Here are 4 companies that offer immune checkpoint inhibitor cancer treatments:

4 Checkpoint Inhibitor Stocks

Stock Returns & Price Chart


Recent Prices &
Annualized Return

Bristol-Myers SquibbBMY
Roche Holding AGRHHBY
Price data from Quandl as of most recent close.

To inspect the performance of the Checkpoint Inhibitor Stocks portfolio, see the chart below. Portfolio values are computed using monthly closes for stocks from Quandl.

The 3 stocks included in the portfolio computations are: AZN, BMY and MRK. The current value of the portfolio assumes that $3,333.33 was invested (total of $10,000) in each stock at its closing monthly price for the first date shown on the portfolio value chart below. All prices are adjusted for splits and dividends. RHHBY was excluded from the portfolio computations because of insufficient price data.

The current value of a $10,000 investment is $35,740. The percent return is 257.40%. The annualized return is 13.58%.

Return Summary for Checkpoint Inhibitor Stocks
Start DateMay-29-2009
Start Investment$10,000.00
End DateMay-24-2019
Current Value of Investment$35,740.27
Total Return257.40%
Annualized Return13.58%
Min DateMay-29-2009
Min Price$10,000.00
Max DateFeb-28-2019
Max Price$37,394.20
# Values121
Number Returns7,260
Number Profitable Returns6,875
Percent Profitable Returns94.70%
Number Unprofitable Returns385
Percent Unprofitable Returns5.30%
Profitable to Unprofitable Returns Ratio17.86

NOTE: The stocks included in the tables and chart are representative of the industry. They are not recommendations.

Related Portfolios

Portfolio of Big Pharma and Biotech Cancer Immunotherapy Stocks

Portfolio of Cancer Immunotherapy Stocks

Portfolio of Biotech Stocks

Portfolio of Biotech Stocks: Diabetes